Digital pathology company Proscia announced on Tuesday it has raised $23 million in a Series B funding round.
The Philadelphia-based firm said that the financing will go toward accelerating its commercial expansion and ramping up its global sales, marketing, and support teams. Proscia also plans on expanding its data assets and AI application portfolio, and the financing will help the firm progress its regulatory strategy to obtain approval from the US Food and Drug Administration for its products.
Scale Venture Partners led the Series B round and was joined by Hitachi Ventures.